New antibody drug aims to ease skin damage in transplant survivors

NCT ID NCT07011810

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 08, 2026 · Updated 16 times

Summary

This study tests a drug called axatilimab for people whose skin becomes thick and hard after a donor stem cell transplant, a condition called sclerotic chronic graft-versus-host disease. About 50 adults will receive the drug to see if it can improve skin symptoms and prevent further damage. The goal is to find a better treatment with fewer side effects than current options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States

Contact
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Moffitt Cancer Center
NOT_YET_RECRUITING

Tampa, Florida, 33612, United States

Contact

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VERSUS HOST DISEASE